(Q40376849)

20 September 2017

Paradoxical response during antituberculous therapy in a patient discontinuing infliximab: a case report (English)

1 reference

20 September 2017

Young Kyung Yoon

1

1 reference

20 September 2017

Jeong Yeon Kim

2

1 reference

20 September 2017

Jang Wook Sohn

3

1 reference

20 September 2017

Min Ja Kim

4

1 reference

20 September 2017

Ja Seol Koo

5

1 reference

20 September 2017

Jai Hyun Choi

6

1 reference

20 September 2017

Dae Won Park

7

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 April 2009

1 reference

Journal of Medical Case Reports

20 September 2017

1 reference

20 September 2017

3

1 reference

20 September 2017

6673

1 reference

Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome

20 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726479

TNF-blocking agents and tuberculosis: new drugs illuminate an old topic

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726479

Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726479

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726479

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726479

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726479

Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726479

A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726479

Recommendations for the prevention and management of tuberculosis in patients taking infliximab

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726479

Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab

20 August 2018

1 reference

12 December 2020

Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis

1 reference

12 December 2020

Mycobacterium tuberculosisInfection in Solid‐Organ Transplant Recipients: Impact and Implications for Management

1 reference

12 December 2020

Paradoxical response to anti-tuberculous drugs: resolution with corticosteroid therapy

1 reference

12 December 2020

Risk Factors for Development of Paradoxical Response During Antituberculosis Therapy in HIV-Negative Patients

1 reference

12 December 2020

Identifiers

DOI

10.1186/1752-1947-3-6673

1 reference

Dimensions Publication ID

20 September 2017

0 references

1 reference

20 September 2017

PubMed publication ID

19830122

1 reference